Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride is used in the treatment of: - breast, ovarian, stomach, lung and colorectal cancer - malignant lymphoma e.g. hodgkin's disease and non-hodgkin's lymphoma - multiple myeloma - non-invasive bladder cancer epirubicin is also used to help prevent recurrence of bladder cancer after surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - 1. relief of subjective and objective symptoms in the following diseases: acute leukaemia, malignant lymphoma, breast cancer, ovarian cancer, stomach cancer, liver cancer, urothelial cancer (bladder cancer, renal pelvic/ureteral cancer) 2. treatment of the following malignant cancer in conjunction with other anti-malignant cancer drugs: breast cancer (pre- and post-operative chemotherapy in operable cases)

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - 1. relief of subjective and objective symptoms in the following diseases: acute leukaemia, malignant lymphoma, breast cancer, ovarian cancer, stomach cancer, liver cancer, urothelial cancer (bladder cancer, renal pelvic/ureteral cancer) 2. treatment of the following malignant cancer in conjunction with other anti-malignant cancer drugs: breast cancer (pre- and post-operative chemotherapy in operable cases)

Canada - English - Health Canada

pfizer canada ulc - epirubicin hydrochloride - solution - 2mg - epirubicin hydrochloride 2mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride ? the active substance in farmorubicin ? belongs to a group of active substances known as anthracyclines. these cell-damaging active substances are used to treat cancer. epirubicin is used alone or in combination with other medicines for the treatment of the following types of cancer: ? breast cancer ? stomach cancer ? lung cancer ? ovarian cancer ? prostate cancer ? colon cancer ? soft tissue sarcomas (malignant tumours of the soft tissue such as fatty tissue, muscle tissue or connective tissue) epirubicin is also used intravesically (i.e. administration into the bladder) to treat early (superficial) cancer of the bladder or to prevent the recurrence of bladder cancer following surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride is indicated for the treatment of a group of neoplastic conditions including: for intravenous administration: - breast cancer - gastro-esophageal cancer - small-cell lung cancer - advanced ovarian cancer - soft-tissue and bone sarcomas when administered intravesically, epirubicin has been shown to be beneficial in the treatment of: - papillary transitional cell bladder cancer - carcinoma-in-situ of the bladder - intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - epirubicin hydrochloride is indicated for the treatment of a group of neoplastic conditions including: for intravenous administration: - breast cancer - gastro-esophageal cancer - small-cell lung cancer - advanced ovarian cancer - soft-tissue and bone sarcomas when administered intravesically, epirubicin has been shown to be beneficial in the treatment of: - papillary transitional cell bladder cancer - carcinoma-in-situ of the bladder - intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - pharmorubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of: ? breast cancer ? gastric cancer ? ovarian cancer ? small cell lung cancer ? lymphoma (non-hodgkin?s lymphoma) ? advanced/metastatic soft tissue sarcoma ? superficial bladder cancer (tis, ta) in bladder cancer, pharmorubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3).